Henrik Simonsen, CFO, Nuevolution explains that his biotech company is listed on the Nasdaq First North Premier Exchange, a Stockholm-based growth stock exchange.
Neuvolution have unique tablet-based medications for the treatment of chronic diseases such as cancer and inflammatory diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis.
Neuvolution have said they expect partnership agreements within three to twelve months 'which we have seen in the past has been a significant trigger for the share price'. They are looking to partner with big pharma and biotech companies.
Neuvolution are at the pre-clinical stage of development and are conducting trials with animals currently.
This interview is one of a series with Edison pharma clients shot at the Biotech and Money Conference at the Waldorf Hotel, London on 14.11.2017.
